The Homegrown Fertilizer Act directs the Secretary of Agriculture to provide grants and loans to help American businesses build or expand domestic fertilizer production facilities. This funding supports various activities such as constructing new plants, purchasing equipment, and improving manufacturing efficiency, with priority given to projects that increase competition and reduce fertilizer prices for farmers. Eligible recipients include independent businesses, cooperatives, nonprofits, and tribal organizations located within the United States, provided they do not already control a large market share in fertilizer production. Grants can reach up to $100 million and require matching funds from recipients, while loans follow existing federal farm program terms. The program also includes conditions requiring repayment if the funded facility is sold to a large market player within 10 years.
The Rural Hospital Revitalization Act of 2026 would direct the Secretary of Agriculture to provide temporary zero-percent interest loans to eligible rural hospitals for building new facilities or renovating existing ones. To qualify, hospitals must be located in counties with fewer than 20,000 people, be at least 35 miles from the nearest hospital, have been licensed for at least 30 years, and demonstrate financial stability. After five years, hospitals would be assessed to determine if they can refinance the loan at standard rates, with options for one-time renewals if they lack sufficient financial strength. The bill also allows qualifying hospitals to receive technical assistance grants to improve operations and financial stability during the loan period.
This bill directs the U.S. Trade Representative to investigate whether Canada's Online Streaming Act unfairly targets American streaming companies by imposing discriminatory taxes and content requirements. It authorizes the Trade Representative to consult with affected U.S. businesses and trade partners, then potentially take retaliatory trade actions if Canada does not amend the measures. The legislation also requires regular reporting to Congress on Canada's implementation of these policies and extends similar investigative powers to other countries with comparable digital trade restrictions.
The ISLET Act amends federal regulations to allow the use of human cadaveric islets for transplantation without classifying them as drugs or biological products. This change directly affects patients with diabetes who may receive islet cell transplants and the healthcare providers who administer these procedures. The bill requires the Secretary of Health and Human Services to update existing regulations within one year and submit a progress report to Congress within six months. By removing islets from drug and biological product categories, the legislation aims to streamline regulatory oversight for this specific type of medical treatment.
This bill establishes a task force to study how artificial intelligence speech-to-text and automatic speech recognition technologies are used in federal and state courts across the United States. The 15-member group, composed of government officials, legal experts, and technology specialists, will examine issues like accuracy, privacy, civil liberties, and costs associated with these AI tools in judicial proceedings. Within 18 months of enactment, the task force must submit a final report to Congress detailing its findings on whether AI affects court record quality, impacts individuals with speech impediments, creates cybersecurity risks, and recommends any necessary policy changes. The task force will also provide quarterly status updates to congressional committees and will dissolve once its final report is submitted.
This bill clarifies when franchisors can be held legally responsible for franchisee employees' pay and working conditions under federal labor laws. It specifies that franchisors are only joint employers if they exercise "substantial direct and immediate control" over essential employment terms like wages, hours, hiring, or discipline - excluding routine brand standards or training. The law explicitly states that franchisors do not become joint employers for actions like setting operating hours, minimum staffing levels, or offering brand guidelines. This directly affects franchisors, franchisees, and their employees by reducing legal uncertainty in the $825 billion franchise sector.
The Pathways to Prosperity Act creates a new grant program to strengthen workforce development at community colleges. It provides competitive grants to community colleges to develop programs that prepare students for high-skill, high-wage jobs through partnerships with employers in growing industries. The bill requires colleges to use proven methods, create credentials that can be used across different jobs or built upon for further training, and track outcomes like program completion and job advancement. It also establishes performance metrics for program evaluation and requires transparent public reporting of results. This legislation primarily affects community colleges, students, and workers seeking career advancement in specific industry sectors.
S 2903, the Safe Step Act, requires health insurance plans and employers offering health coverage to establish a clear, timely process for patients or doctors to request exceptions when step therapy protocols (where insurers require trying cheaper drugs first) would harm a patient. It mandates approval for exceptions if prior drugs failed, delay would cause severe harm, a drug is unsafe, or a patient is stable on their current medication. Plans must respond to requests within 72 hours (or 24 hours in emergencies) and cover the requested drug without extra cost-sharing. The bill also requires annual reports to the government on exception requests, approvals, denials, and trends by medical condition or specialty. This directly affects patients on health plans with step therapy, their doctors, and the insurers managing those plans.
This bill directs the U.S. Department of Health and Human Services to fund research on early detection and treatment of uterine fibroids (non-cancerous uterine tumors) and to award grants to states. The grants will support state programs that increase early detection through screening (like advanced imaging), patient navigation services, public education campaigns, and implementing research-backed strategies. It also requires additional research on disparities in pain management during fibroid surgery and conditions like Asherman’s Syndrome. States receiving grants must report on program outcomes and research findings to Congress every two years. The bill directly affects healthcare systems, providers, and patients - particularly those facing disparities in gynecological care - by expanding access to early detection services.
S 2287, the Palliative Care and Hospice Education and Training Act, establishes federal funding to expand training for health professionals in palliative and hospice care. The bill creates multiple programs including grants for education programs, fellowships for faculty to gain specialized training, and career incentive awards for students pursuing palliative care specialties. It prioritizes training in rural and underserved areas, for pediatric populations, and for racial and ethnic minorities. The bill authorizes $15 million annually through 2030 to build a more skilled palliative care workforce for patients with serious or life-threatening illnesses.
This bill (S 1677, Ensuring Lasting Smiles Act) requires health insurance plans to cover medically necessary treatments for congenital anomalies or birth defects affecting the eyes, ears, teeth, mouth, or jaw. It mandates coverage for reconstructive services, dental/orthodontic care, and related treatments during the course of medical treatment, while excluding purely cosmetic procedures not medically necessary. Plans may apply cost-sharing requirements similar to those for other medical services but must provide notice about these coverage requirements to participants by January 1, 2026. The bill also directs a study on provider network adequacy and cost impacts related to these coverage requirements, to be completed by December 2027.
The HELP Copays Act requires that financial assistance from non-profit organizations or prescription drug manufacturers counts toward patients' annual out-of-pocket cost-sharing limits (like deductibles and copays) for certain prescription drugs. It directly affects individuals enrolled in group health plans or individual insurance who receive such assistance, ensuring payments from these sources reduce their total out-of-pocket spending. The bill amends key healthcare laws to include these payments in calculating cost-sharing thresholds, specifically for specialty drugs and drugs subject to utilization management (like prior authorization). It takes effect for plan years beginning in 2026 and does not change how utilization management tools are applied.
